USFDA Slams Amneal Pharmaceuticals for “Adulterated” Drug Production, Citing Egregious Sterility Failures

The U.S. Food and Drug Administration (USFDA) has issued a severe warning letter to Amneal Pharmaceuticals, bringing to light critical manufacturing violations at its Gujarat, India facility that have rendered the company’s drug products “adulterated” under U.S. law. The warning, dated August 27, 2025, follows a detailed inspection conducted from March 10 to March 19, 2025, during which investigators found multiple breaches of Current Good Manufacturing Practice (CGMP) regulations (Title 21 CFR Parts 210 and 211).

The most alarming finding concerns the company’s production of ropivacaine hydrochloride injection, an epidural medication. USFDA inspectors discovered that polymeric intravenous (IV) bags used in the manufacturing process were shedding visible white fiber particulates directly into the drug preparations. This contamination poses a significant and immediate risk to patient safety. The USFDA’s letter explicitly warns of severe health consequences, including inflammation, epidural abscess, meningitis, and potentially irreversible spinal cord damage or permanent nerve injury.

Further investigation by the USFDA revealed a troubling history of the issue. The company had been aware of the polypropylene bags as a source of contamination since late 2022 and early 2023. Instead of correcting the root cause, Amneal’s internal investigation was deemed “inadequate,” and the company astonishingly “relaxed the rejection thresholds” to continue using the defective components. This decision allowed flawed products to enter the supply chain, a practice the USFDA found completely unacceptable.

The USFDA also criticized Amneal’s delayed and reactive response. The company only initiated a Field Alert Report on March 26, 2025—after the USFDA’s inspection team had already documented the deficiencies. A nationwide recall of the affected ropivacaine hydrochloride lots was not announced until April 18, 2025. Industry observers and regulatory experts have pointed out that these critical safety measures were only taken as a direct result of the USFDA’s intervention, not as a proactive move by the company itself.

In a statement to the media, an Amneal spokesperson downplayed the severity of the letter, noting that it did not necessitate a halt in manufacturing or marketing of its approved products. This attempt to frame the warning as a minor issue stands in stark contrast to the USFDA’s findings of “adulterated” drugs and systemic quality control failures.

The warning letter places significant pressure on Amneal to undertake comprehensive corrective and preventive actions (CAPA). According to the Generic Drug User Fee Amendments (GDUFA III) for fiscal years 2023–2027, the company’s Gujarat facility is eligible to request a Post-Warning Letter Meeting. This meeting would allow Amneal to discuss its remediation strategy with the USFDA and demonstrate a credible plan for resolving the documented violations. However, the agency is likely to demand a thorough, transparent, and systemic overhaul of the facility’s quality control systems to prevent any recurrence of these life-threatening contamination issues. Failure to comply fully and promptly could lead to more severe enforcement actions, including the refusal of new drug approvals and potential import alerts.